ICC 2019

Yi Li

Yi Li, Speaker at Cancer Congress
XiangXue Life Sciences Research Centre, XiangXue Pharmaceutical Co. Ltd, China
Title : Immunotherapy of solid tumor with the third generation of TCR-T TAEST16001


T-cell triggering thresholds can be edited by engineered TCR with enhanced affinity. TAEST (TCR affinity enhanced specific T-cells) for NY-ESO-1 was generated, and the TCR had 29 X higher affinity to its antigen vs wild type T-cells and with good (80-90%+) expression. There was good in vitro (CTL/ELISPOT) and in vivo efficacy with strong evidence of tumor specific TAEST infiltration. TAEST, with its enhanced TCR affinity, is safe and showed encouraging efficacy (4/7 showed response and 3/7 SD) and safety profile in a Phase I study. Lymphodepletion pretreatment appeared to be critical for efficacy/cytokine response/persistence of TAEST cells.


Yi Li Ph.D., Principal Investigator at GIBH (Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences), CSO at XLifeSc (Guangdong Xiangxue Life Sciences, Ltd.). Dr. Li gained his PhD in Antibody Engineering at the University of Leicester, UK in 1996. After a one-year post-doctor training in 1997, he had been a research scientist, department head and director for several companies, including Immunocore/Medigen/ Avidex, Biovation/Meck KgA and ADAS UK. In 2011, he has joined GIBH, and State Key Laboratory of Respiratory Disease, and has been currently holding positions of Principal Investigator.